Duration of relative protection of screening for cervical cancer

David D Celentano, Ann C. Klassen, Carol S. Weisman, Neil B. Rosenshein

Research output: Contribution to journalArticle

Abstract

The reduction in cervical cancer among women with at least one previous negative Pap smear can be assessed in terms of the time elapsed since the last smear was taken. One indicator of the utility of screening is the duration of relative protection, commonly calculated as the inverse of the disease odds ratio. Most investigations of the extent of relative protection provided by Pap testing have relied on data from centrally organized screening programs or case-control studies. For geographic areas without mass screening programs or tumor registries, reliance on subject recall of Pap tests is required. We conducted a case-control investigation of cervical cancer and interviewed 153 Maryland women with invasive disease and two control groups: 153 case-nominated controls and 392 randomly selected controls. The duration of relative protection of screening for disease was 4-6 years for both control groups [relative protection (RP) = 4.30, 95% confidence interval (CI) = 1.5-12.7 for neighborhood controls, RP = 3.63, 95% CI = 1.4-9.6 for random controls]. These findings held after adjusting for education, ever treated for a sexually transmitted disease, smoking, age at menarche and at first sexual intercourse, number of pregnancies, lifetime contraceptive use, and utilization of obstetrician-gynecologist services; the RPs increased upon adjustment. However, there was a decline in the RP with increased duration. Our findings are directly comparable to reports where smears have been verified, suggesting that self-reports of previous tests may be reliable as a method to evaluate the utility of screening.

Original languageEnglish (US)
Pages (from-to)411-422
Number of pages12
JournalPreventive Medicine
Volume18
Issue number4
DOIs
StatePublished - 1989

Fingerprint

Uterine Cervical Neoplasms
Papanicolaou Test
Coitus
Confidence Intervals
Social Adjustment
Control Groups
Mass Screening
Menarche
Sexually Transmitted Diseases
Contraceptive Agents
Self Report
Registries
Case-Control Studies
Smoking
Odds Ratio
Education
Pregnancy
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Duration of relative protection of screening for cervical cancer. / Celentano, David D; Klassen, Ann C.; Weisman, Carol S.; Rosenshein, Neil B.

In: Preventive Medicine, Vol. 18, No. 4, 1989, p. 411-422.

Research output: Contribution to journalArticle

Celentano, David D ; Klassen, Ann C. ; Weisman, Carol S. ; Rosenshein, Neil B. / Duration of relative protection of screening for cervical cancer. In: Preventive Medicine. 1989 ; Vol. 18, No. 4. pp. 411-422.
@article{acb2798220804ef1a1c8dd75e966f174,
title = "Duration of relative protection of screening for cervical cancer",
abstract = "The reduction in cervical cancer among women with at least one previous negative Pap smear can be assessed in terms of the time elapsed since the last smear was taken. One indicator of the utility of screening is the duration of relative protection, commonly calculated as the inverse of the disease odds ratio. Most investigations of the extent of relative protection provided by Pap testing have relied on data from centrally organized screening programs or case-control studies. For geographic areas without mass screening programs or tumor registries, reliance on subject recall of Pap tests is required. We conducted a case-control investigation of cervical cancer and interviewed 153 Maryland women with invasive disease and two control groups: 153 case-nominated controls and 392 randomly selected controls. The duration of relative protection of screening for disease was 4-6 years for both control groups [relative protection (RP) = 4.30, 95{\%} confidence interval (CI) = 1.5-12.7 for neighborhood controls, RP = 3.63, 95{\%} CI = 1.4-9.6 for random controls]. These findings held after adjusting for education, ever treated for a sexually transmitted disease, smoking, age at menarche and at first sexual intercourse, number of pregnancies, lifetime contraceptive use, and utilization of obstetrician-gynecologist services; the RPs increased upon adjustment. However, there was a decline in the RP with increased duration. Our findings are directly comparable to reports where smears have been verified, suggesting that self-reports of previous tests may be reliable as a method to evaluate the utility of screening.",
author = "Celentano, {David D} and Klassen, {Ann C.} and Weisman, {Carol S.} and Rosenshein, {Neil B.}",
year = "1989",
doi = "10.1016/0091-7435(89)90001-7",
language = "English (US)",
volume = "18",
pages = "411--422",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Duration of relative protection of screening for cervical cancer

AU - Celentano, David D

AU - Klassen, Ann C.

AU - Weisman, Carol S.

AU - Rosenshein, Neil B.

PY - 1989

Y1 - 1989

N2 - The reduction in cervical cancer among women with at least one previous negative Pap smear can be assessed in terms of the time elapsed since the last smear was taken. One indicator of the utility of screening is the duration of relative protection, commonly calculated as the inverse of the disease odds ratio. Most investigations of the extent of relative protection provided by Pap testing have relied on data from centrally organized screening programs or case-control studies. For geographic areas without mass screening programs or tumor registries, reliance on subject recall of Pap tests is required. We conducted a case-control investigation of cervical cancer and interviewed 153 Maryland women with invasive disease and two control groups: 153 case-nominated controls and 392 randomly selected controls. The duration of relative protection of screening for disease was 4-6 years for both control groups [relative protection (RP) = 4.30, 95% confidence interval (CI) = 1.5-12.7 for neighborhood controls, RP = 3.63, 95% CI = 1.4-9.6 for random controls]. These findings held after adjusting for education, ever treated for a sexually transmitted disease, smoking, age at menarche and at first sexual intercourse, number of pregnancies, lifetime contraceptive use, and utilization of obstetrician-gynecologist services; the RPs increased upon adjustment. However, there was a decline in the RP with increased duration. Our findings are directly comparable to reports where smears have been verified, suggesting that self-reports of previous tests may be reliable as a method to evaluate the utility of screening.

AB - The reduction in cervical cancer among women with at least one previous negative Pap smear can be assessed in terms of the time elapsed since the last smear was taken. One indicator of the utility of screening is the duration of relative protection, commonly calculated as the inverse of the disease odds ratio. Most investigations of the extent of relative protection provided by Pap testing have relied on data from centrally organized screening programs or case-control studies. For geographic areas without mass screening programs or tumor registries, reliance on subject recall of Pap tests is required. We conducted a case-control investigation of cervical cancer and interviewed 153 Maryland women with invasive disease and two control groups: 153 case-nominated controls and 392 randomly selected controls. The duration of relative protection of screening for disease was 4-6 years for both control groups [relative protection (RP) = 4.30, 95% confidence interval (CI) = 1.5-12.7 for neighborhood controls, RP = 3.63, 95% CI = 1.4-9.6 for random controls]. These findings held after adjusting for education, ever treated for a sexually transmitted disease, smoking, age at menarche and at first sexual intercourse, number of pregnancies, lifetime contraceptive use, and utilization of obstetrician-gynecologist services; the RPs increased upon adjustment. However, there was a decline in the RP with increased duration. Our findings are directly comparable to reports where smears have been verified, suggesting that self-reports of previous tests may be reliable as a method to evaluate the utility of screening.

UR - http://www.scopus.com/inward/record.url?scp=0024375629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024375629&partnerID=8YFLogxK

U2 - 10.1016/0091-7435(89)90001-7

DO - 10.1016/0091-7435(89)90001-7

M3 - Article

C2 - 2678092

AN - SCOPUS:0024375629

VL - 18

SP - 411

EP - 422

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

IS - 4

ER -